Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide is an experimental small molecule belonging to the biphenyldicarboxamides chemical class. It has a molecular formula of C22H24N2O2 and a molecular weight of approximately 348.44 g/mol[1][2][8]. The compound has been studied as a potent inhibitor of mitogen‑activated protein kinase 14 (MAPK14/p38α), with reported IC50 and Ki values in the low nanomolar range[1]. It also shows inhibitory activity against cytochrome P450 enzymes CYP2C19 and CYP1A2 at higher concentrations[6]. There are no approved indications or clinical trials beyond preclinical/experimental stages for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide.